Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission

Table 2 Patients’ characteristics n (%)

Numbers of patients	30
Gender (male/female)	18/12
Age [mean ± SD (range), yr]	48.6 ± 13.3 (24-67)
Disease duration [mean ± SD (range), yr]	13.9 ± 9.5 (1-32)
Inpatient/outpatient	0/30
History of abdominal surgery	2 (6.7)
Type of disease
Total colitis	19 (63.3)
Left-sided	10 (33.3)
Proctitis	1 (3.3)
Disease activity (Rachmilewitz index)
CAI = 0	19 (63.3)
CAI = 1	4 (13.3)
CAI = 2	4 (13.3)
CAI = 3	2 (6.7)
CAI = 4	1 (3.3)
Serum albumin (mean ± SD, g/dL)	4.2 ± 0.5
Serum CRP (mean ± SD, mg/dL)	0.11 ± 0.15
Medications
5-ASA	24 (80.0)
Steroid	4 (13.3)
Thiopurines	12 (40.0)
Anti-TNF-Ab	1 (3.3)
No medication	1 (3.3)
Observation period after CCE; median (range)	20.5 (5-27)

CAI: Clinical activity index; 5-ASA: 5-aminosalicylic acid; SD: Standard deviation; CRP: C-reactive protein; CCE: Colon capsule endoscopy.